TSRO up +2.68% percent Today $TSRO High is at 27.6
Post# of 81
Posted On: 11/10/2014 3:48:04 PM
TSRO up +2.68% percent Today $TSRO High is at 27.63 and the Low 26.27 with current volume of 155,613.
Recent News posted below.
Tesaro Inc TSRO other info.
http://investorshangout.com/TESARO-Inc-TSRO-90062/
TSRO Tesaro Inc Recent Headline News
TESARO's (TSRO) CEO Lonnie Moulder on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 07, 1:31AM CST
TSRO: 28.10 (+1.62)
Tesaro beats 3Q profit forecasts
Automated Insights - Thu Nov 06, 4:04AM CST
WALTHAM, Mass. (AP) _ Tesaro Inc. (TSRO) on Thursday reported a third-quarter loss of $36.2 million.
TSRO: 28.10 (+1.62)
Tesaro beats by $0.03
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:07PM CST
TSRO: 28.10 (+1.62)
TESARO Announces Third-Quarter 2014 Operating Results
GlobeNewswire - Wed Nov 05, 3:36PM CST
-- Oral Rolapitant New Drug Application (NDA) Accepted for Review by U.S. FDA
TSRO: 28.10 (+1.62)
Tesaro reports November 5
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 4:34PM CDT
TSRO: 28.10 (+1.62)
Tesaro to Announce Third-Quarter 2014 Financial Results on November 5, 2014
GlobeNewswire - Wed Oct 22, 3:01PM CDT
TESARO, Inc. (Nasdaq:TSRO) will announce its third-quarter 2014 financial results on Wednesday, November 5, 2014, after the close of the U.S. financial markets. TESARO's senior management team will host a conference call and live audio webcast at 4:15 p.m. ET on November 5, 2014 to discuss the Company's results in greater detail.
TSRO: 28.10 (+1.62)
TESARO Announces Closing of $201.25 Million Public Offering of 3.00% Convertible Senior Notes Due 2021, Including Full Exercise of the Underwriters' Option to Purchase Additional Notes
GlobeNewswire - Mon Sep 29, 3:01PM CDT
TESARO, Inc. (Nasdaq:TSRO) announced today the closing of its previously announced underwritten public offering of $201.25 million aggregate principal amount of its 3.00% convertible senior notes due 2021 (the "notes"
, including the notes issued pursuant to the full exercise of the underwriters' option to purchase up to $26.25 million aggregate principal amount of additional notes on the same terms and conditions. As a result, aggregate net proceeds to TESARO, after deducting the underwriting discount and estimated offering expenses payable by TESARO, will be approximately $194.71 million.
TSRO: 28.10 (+1.62), DB: 29.99 (-0.25)
Weakness Seen in Tesaro, Inc. (TSRO): Stock Tumbles 9.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 7:54AM CDT
Make sure to keep a close watch on Tesaro in the near future, and especially on earnings estimates following the recent slump.
TSRO: 28.10 (+1.62)
TESARO Announces Pricing of $175 Million of 3.00% Convertible Senior Notes Due 2021
GlobeNewswire - Tue Sep 23, 9:40PM CDT
TESARO, Inc. (Nasdaq:TSRO) announced today the pricing of $175 million aggregate principal amount of its 3.00% convertible senior notes due 2021 (the "notes" in an underwritten public offering. The size of the offering was increased from the previously announced aggregate principal amount of $165 million. TESARO has granted the underwriters a 30-day option to purchase up to $26.25 million aggregate principal amount of additional notes on the same terms and conditions to cover over-allotments. The offering is expected to close on or about September 29, 2014, subject to customary closing conditions.
TSRO: 28.10 (+1.62), DB: 29.99 (-0.25)
Nasdaq stocks posting largest percentage decreases
AP - Tue Sep 23, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
UBNT: 29.34 (+0.56), TSRO: 28.10 (+1.62), WATT: 9.50 (+0.22), MLAB: 83.26 (+0.34), NVC.TO: 6.40 (+0.10), NVCN: 5.80 (+0.02), PBSK: 14.79 (-0.11)
TESARO Announces Offering of $165 Million of Convertible Senior Notes Due 2021
GlobeNewswire - Mon Sep 22, 3:46PM CDT
TESARO, Inc. (Nasdaq:TSRO) announced today that, subject to market and other conditions, it intends to offer $165 million aggregate principal amount of convertible senior notes due 2021 (the "notes" in an underwritten public offering. TESARO also expects to grant the underwriters a 30-day option to purchase up to $24.75 million aggregate principal amount of additional notes on the same terms and conditions to cover over-allotments. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
TSRO: 28.10 (+1.62), DB: 29.99 (-0.25)
TESARO Seeks FDA Approval for NK-1 Receptor Rolapitant - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 4:00PM CDT
TESARO, Inc. (TSRO) submitted a new drug application for its pipeline candidate, oral rolapitant, to the FDA.
ENDP: 69.01 (+0.05), TSRO: 28.10 (+1.62), OPK: 8.67 (+0.35), MRK: 58.77 (-0.57)
OPKO Licensee TESARO Submits New Drug Application for Rolapitant
Business Wire - Mon Sep 08, 11:20AM CDT
OPKO Health, Inc. (NYSE:OPK), reported that its licensee, TESARO, Inc. (Nasdaq:TSRO), has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of oral rolapitant, an investigational neurokinin-1 (NK-1) receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting (CINV).
TSRO: 28.10 (+1.62), OPK: 8.67 (+0.35)
TESARO Announces Submission of Rolapitant New Drug Application (NDA) to U.S. Food and Drug Administration
GlobeNewswire - Mon Sep 08, 7:06AM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that it has submitted the New Drug Application (NDA) for oral rolapitant to the U.S. Food and Drug Administration (FDA). Rolapitant is an investigational neurokinin-1 (NK-1) receptor antagonist developed for the prevention of chemotherapy-induced nausea and vomiting (CINV).
TSRO: 28.10 (+1.62)
TESARO Announces Participation at Several Upcoming Investor Conferences
GlobeNewswire - Thu Aug 21, 7:01AM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, announced that Lonnie Moulder, CEO, Mary Lynne Hedley, Ph.D., President and COO, and Tim Pearson, Executive Vice President and CFO of TESARO, will participate in several upcoming investor conferences during the month of September, including:
TSRO: 28.10 (+1.62)
TESARO (TSRO) Slips on Wider-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 2:10PM CDT
TESARO (TSRO) reported second-quarter loss of $1.00 per share, wider than the Zacks Consensus Estimate of a loss of 89 cents and year-ago loss of 67 cents.
ENDP: 69.03 (+0.07), TSRO: 28.10 (+1.62), SLXP: 93.15 (+1.68), ENTA: 43.92 (+0.59)
TESARO Appoints Mary Lynne Hedley, Ph.D., as Chief Operating Officer
GlobeNewswire - Thu Jul 24, 3:09PM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that Mary Lynne Hedley, Ph.D., President and Co-Founder of TESARO, has been appointed to the role of Chief Operating Officer.
TSRO: 28.10 (+1.62)
TESARO Announces Second-Quarter 2014 Operating Results
GlobeNewswire - Thu Jul 24, 3:09PM CDT
-- Oral Rolapitant New Drug Application (NDA) on Track for Submission to U.S. FDA
TSRO: 28.10 (+1.62)
Myriad Genetics Poised on Strong Fundamentals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 5:10PM CDT
On July 9, we issued an updated research report on leading molecular diagnostic company Myriad Genetics Inc. (MYGN).
BIIB: 327.03 (+6.28), MYGN: 32.98 (-1.91), TSRO: 28.10 (+1.62)
TESARO to Announce Second-Quarter 2014 Financial Results on July 24, 2014
GlobeNewswire - Thu Jul 10, 3:01PM CDT
TESARO, Inc. (Nasdaq:TSRO) will announce its second-quarter 2014 financial results on Thursday, July 24, 2014, after the close of the U.S. financial markets. TESARO's senior management team will host a conference call and live audio webcast at 4:15 p.m. ET on July 24, 2014 to discuss the Company's results in greater detail.
TSRO: 28.10 (+1.62)
Recent News posted below.
Tesaro Inc TSRO other info.
http://investorshangout.com/TESARO-Inc-TSRO-90062/
TSRO Tesaro Inc Recent Headline News
TESARO's (TSRO) CEO Lonnie Moulder on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 07, 1:31AM CST
TSRO: 28.10 (+1.62)
Tesaro beats 3Q profit forecasts
Automated Insights - Thu Nov 06, 4:04AM CST
WALTHAM, Mass. (AP) _ Tesaro Inc. (TSRO) on Thursday reported a third-quarter loss of $36.2 million.
TSRO: 28.10 (+1.62)
Tesaro beats by $0.03
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:07PM CST
TSRO: 28.10 (+1.62)
TESARO Announces Third-Quarter 2014 Operating Results
GlobeNewswire - Wed Nov 05, 3:36PM CST
-- Oral Rolapitant New Drug Application (NDA) Accepted for Review by U.S. FDA
TSRO: 28.10 (+1.62)
Tesaro reports November 5
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 4:34PM CDT
TSRO: 28.10 (+1.62)
Tesaro to Announce Third-Quarter 2014 Financial Results on November 5, 2014
GlobeNewswire - Wed Oct 22, 3:01PM CDT
TESARO, Inc. (Nasdaq:TSRO) will announce its third-quarter 2014 financial results on Wednesday, November 5, 2014, after the close of the U.S. financial markets. TESARO's senior management team will host a conference call and live audio webcast at 4:15 p.m. ET on November 5, 2014 to discuss the Company's results in greater detail.
TSRO: 28.10 (+1.62)
TESARO Announces Closing of $201.25 Million Public Offering of 3.00% Convertible Senior Notes Due 2021, Including Full Exercise of the Underwriters' Option to Purchase Additional Notes
GlobeNewswire - Mon Sep 29, 3:01PM CDT
TESARO, Inc. (Nasdaq:TSRO) announced today the closing of its previously announced underwritten public offering of $201.25 million aggregate principal amount of its 3.00% convertible senior notes due 2021 (the "notes"
, including the notes issued pursuant to the full exercise of the underwriters' option to purchase up to $26.25 million aggregate principal amount of additional notes on the same terms and conditions. As a result, aggregate net proceeds to TESARO, after deducting the underwriting discount and estimated offering expenses payable by TESARO, will be approximately $194.71 million. TSRO: 28.10 (+1.62), DB: 29.99 (-0.25)
Weakness Seen in Tesaro, Inc. (TSRO): Stock Tumbles 9.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 7:54AM CDT
Make sure to keep a close watch on Tesaro in the near future, and especially on earnings estimates following the recent slump.
TSRO: 28.10 (+1.62)
TESARO Announces Pricing of $175 Million of 3.00% Convertible Senior Notes Due 2021
GlobeNewswire - Tue Sep 23, 9:40PM CDT
TESARO, Inc. (Nasdaq:TSRO) announced today the pricing of $175 million aggregate principal amount of its 3.00% convertible senior notes due 2021 (the "notes"
in an underwritten public offering. The size of the offering was increased from the previously announced aggregate principal amount of $165 million. TESARO has granted the underwriters a 30-day option to purchase up to $26.25 million aggregate principal amount of additional notes on the same terms and conditions to cover over-allotments. The offering is expected to close on or about September 29, 2014, subject to customary closing conditions. TSRO: 28.10 (+1.62), DB: 29.99 (-0.25)
Nasdaq stocks posting largest percentage decreases
AP - Tue Sep 23, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
UBNT: 29.34 (+0.56), TSRO: 28.10 (+1.62), WATT: 9.50 (+0.22), MLAB: 83.26 (+0.34), NVC.TO: 6.40 (+0.10), NVCN: 5.80 (+0.02), PBSK: 14.79 (-0.11)
TESARO Announces Offering of $165 Million of Convertible Senior Notes Due 2021
GlobeNewswire - Mon Sep 22, 3:46PM CDT
TESARO, Inc. (Nasdaq:TSRO) announced today that, subject to market and other conditions, it intends to offer $165 million aggregate principal amount of convertible senior notes due 2021 (the "notes"
in an underwritten public offering. TESARO also expects to grant the underwriters a 30-day option to purchase up to $24.75 million aggregate principal amount of additional notes on the same terms and conditions to cover over-allotments. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. TSRO: 28.10 (+1.62), DB: 29.99 (-0.25)
TESARO Seeks FDA Approval for NK-1 Receptor Rolapitant - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 4:00PM CDT
TESARO, Inc. (TSRO) submitted a new drug application for its pipeline candidate, oral rolapitant, to the FDA.
ENDP: 69.01 (+0.05), TSRO: 28.10 (+1.62), OPK: 8.67 (+0.35), MRK: 58.77 (-0.57)
OPKO Licensee TESARO Submits New Drug Application for Rolapitant
Business Wire - Mon Sep 08, 11:20AM CDT
OPKO Health, Inc. (NYSE:OPK), reported that its licensee, TESARO, Inc. (Nasdaq:TSRO), has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of oral rolapitant, an investigational neurokinin-1 (NK-1) receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting (CINV).
TSRO: 28.10 (+1.62), OPK: 8.67 (+0.35)
TESARO Announces Submission of Rolapitant New Drug Application (NDA) to U.S. Food and Drug Administration
GlobeNewswire - Mon Sep 08, 7:06AM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that it has submitted the New Drug Application (NDA) for oral rolapitant to the U.S. Food and Drug Administration (FDA). Rolapitant is an investigational neurokinin-1 (NK-1) receptor antagonist developed for the prevention of chemotherapy-induced nausea and vomiting (CINV).
TSRO: 28.10 (+1.62)
TESARO Announces Participation at Several Upcoming Investor Conferences
GlobeNewswire - Thu Aug 21, 7:01AM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, announced that Lonnie Moulder, CEO, Mary Lynne Hedley, Ph.D., President and COO, and Tim Pearson, Executive Vice President and CFO of TESARO, will participate in several upcoming investor conferences during the month of September, including:
TSRO: 28.10 (+1.62)
TESARO (TSRO) Slips on Wider-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 2:10PM CDT
TESARO (TSRO) reported second-quarter loss of $1.00 per share, wider than the Zacks Consensus Estimate of a loss of 89 cents and year-ago loss of 67 cents.
ENDP: 69.03 (+0.07), TSRO: 28.10 (+1.62), SLXP: 93.15 (+1.68), ENTA: 43.92 (+0.59)
TESARO Appoints Mary Lynne Hedley, Ph.D., as Chief Operating Officer
GlobeNewswire - Thu Jul 24, 3:09PM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that Mary Lynne Hedley, Ph.D., President and Co-Founder of TESARO, has been appointed to the role of Chief Operating Officer.
TSRO: 28.10 (+1.62)
TESARO Announces Second-Quarter 2014 Operating Results
GlobeNewswire - Thu Jul 24, 3:09PM CDT
-- Oral Rolapitant New Drug Application (NDA) on Track for Submission to U.S. FDA
TSRO: 28.10 (+1.62)
Myriad Genetics Poised on Strong Fundamentals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 5:10PM CDT
On July 9, we issued an updated research report on leading molecular diagnostic company Myriad Genetics Inc. (MYGN).
BIIB: 327.03 (+6.28), MYGN: 32.98 (-1.91), TSRO: 28.10 (+1.62)
TESARO to Announce Second-Quarter 2014 Financial Results on July 24, 2014
GlobeNewswire - Thu Jul 10, 3:01PM CDT
TESARO, Inc. (Nasdaq:TSRO) will announce its second-quarter 2014 financial results on Thursday, July 24, 2014, after the close of the U.S. financial markets. TESARO's senior management team will host a conference call and live audio webcast at 4:15 p.m. ET on July 24, 2014 to discuss the Company's results in greater detail.
TSRO: 28.10 (+1.62)
(0)
(0)TESARO Inc. (TSRO) Stock Research Links
Scroll down for more posts ▼